 | • レポートコード：GIR-2104Z00800 • 出版社/出版日：GlobalInfoResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、107ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療・医薬品 |
| Single User | ￥504,600 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥756,900 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,009,200 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、アルツハイマー病用パイプライン薬のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。アルツハイマー病用パイプライン薬の種類別市場規模（Namenda、Ebixa、Axura、Aricept、Nootropil、Exelon、Memary、Solanezumab、LuAe58054）、用途別市場規模（病院、ドラッグストア）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・アルツハイマー病用パイプライン薬の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Forest Laboratorie、Eisai、H. Lundbeck A/S、Novartis、Merz GmbH & Co. KGaA、Johnson & Johnson、UCB ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：Namenda、Ebixa、Axura、Aricept、Nootropil、Exelon、Memary、Solanezumab、LuAe58054 ・用途別分析2016年-2026年：病院、ドラッグストア ・アルツハイマー病用パイプライン薬の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・アルツハイマー病用パイプライン薬のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・アルツハイマー病用パイプライン薬のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・アルツハイマー病用パイプライン薬の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・アルツハイマー病用パイプライン薬の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Alzheimer’s Pipeline Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Alzheimer’s Pipeline Drugs size is estimated to be xx million in 2020 from USD xx million in 2019, with a change of XX% between 2019 and 2020. The global Alzheimer’s Pipeline Drugs market size is expected to grow at a CAGR of xx% for the next five years.
Market segmentation
Alzheimer’s Pipeline Drugs market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Namenda
Ebixa
Axura
Aricept
Nootropil
Exelon
Memary
Solanezumab
LuAe58054
Market segment by Application can be divided into
Hospital
Drug Store
The key market players for global Alzheimer’s Pipeline Drugs market are listed below:
Forest Laboratorie
Eisai
H. Lundbeck A/S
Novartis
Merz GmbH & Co. KGaA
Johnson & Johnson
UCB
Market segment by Region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
1 Market Overview
1.1 Alzheimer’s Pipeline Drugs Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Alzheimer’s Pipeline Drugs Revenue by Type: 2019 Versus 2021 Versus 2026
1.2.2 Namenda
1.2.3 Ebixa
1.2.4 Axura
1.2.5 Aricept
1.2.6 Nootropil
1.2.7 Exelon
1.2.8 Memary
1.2.9 Solanezumab
1.2.10 LuAe58054
1.3 Market Analysis by Application
1.3.1 Overview: Global Alzheimer’s Pipeline Drugs Revenue by Application: 2019 Versus 2021 Versus 2026
1.3.2 Hospital
1.3.3 Drug Store
1.4 Global Alzheimer’s Pipeline Drugs Market Size & Forecast
1.4.1 Global Alzheimer’s Pipeline Drugs Sales in Value (2016-2026))
1.4.2 Global Alzheimer’s Pipeline Drugs Sales in Volume (2016-2026)
1.4.3 Global Alzheimer’s Pipeline Drugs Price by Type (2016-2026) & (USD/Unit)
1.5 Global Alzheimer’s Pipeline Drugs Production Capacity Analysis
1.5.1 Global Alzheimer’s Pipeline Drugs Total Production Capacity (2016-2026)
1.5.2 Global Alzheimer’s Pipeline Drugs Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Alzheimer’s Pipeline Drugs Market Drivers
1.6.2 Alzheimer’s Pipeline Drugs Market Restraints
1.6.3 Alzheimer’s Pipeline Drugs Trends Analysis
2 Manufacturers Profiles
2.1 Forest Laboratorie
2.1.1 Forest Laboratorie Details
2.1.2 Forest Laboratorie Major Business
2.1.3 Forest Laboratorie Alzheimer’s Pipeline Drugs Product and Services
2.1.4 Forest Laboratorie Alzheimer’s Pipeline Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.2 Eisai
2.2.1 Eisai Details
2.2.2 Eisai Major Business
2.2.3 Eisai Alzheimer’s Pipeline Drugs Product and Services
2.2.4 Eisai Alzheimer’s Pipeline Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.3 H. Lundbeck A/S
2.3.1 H. Lundbeck A/S Details
2.3.2 H. Lundbeck A/S Major Business
2.3.3 H. Lundbeck A/S Alzheimer’s Pipeline Drugs Product and Services
2.3.4 H. Lundbeck A/S Alzheimer’s Pipeline Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.4 Novartis
2.4.1 Novartis Details
2.4.2 Novartis Major Business
2.4.3 Novartis Alzheimer’s Pipeline Drugs Product and Services
2.4.4 Novartis Alzheimer’s Pipeline Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.5 Merz GmbH & Co. KGaA
2.5.1 Merz GmbH & Co. KGaA Details
2.5.2 Merz GmbH & Co. KGaA Major Business
2.5.3 Merz GmbH & Co. KGaA Alzheimer’s Pipeline Drugs Product and Services
2.5.4 Merz GmbH & Co. KGaA Alzheimer’s Pipeline Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.6 Johnson & Johnson
2.6.1 Johnson & Johnson Details
2.6.2 Johnson & Johnson Major Business
2.6.3 Johnson & Johnson Alzheimer’s Pipeline Drugs Product and Services
2.6.4 Johnson & Johnson Alzheimer’s Pipeline Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.7 UCB
2.7.1 UCB Details
2.7.2 UCB Major Business
2.7.3 UCB Alzheimer’s Pipeline Drugs Product and Services
2.7.4 UCB Alzheimer’s Pipeline Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
3 Alzheimer’s Pipeline Drugs Sales by Manufacturer
3.1 Global Alzheimer’s Pipeline Drugs Sales in Volume by Manufacturer (2019-2021e)
3.2 Global Alzheimer’s Pipeline Drugs Revenue by Manufacturer (2019-2021e)
3.3 Key Manufacturer Market Position in Alzheimer’s Pipeline Drugs
3.4 Market Concentration Rate
3.4.1 Top 3 Alzheimer’s Pipeline Drugs Manufacturer Market Share
3.4.2 Top 6 Alzheimer’s Pipeline Drugs Manufacturer Market Share
3.5 Global Alzheimer’s Pipeline Drugs Production Capacity by Company
3.6 Manufacturer by Geography: Head Office and Alzheimer’s Pipeline Drugs Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Alzheimer’s Pipeline Drugs Market Size by Region
4.1.1 Global Alzheimer’s Pipeline Drugs Sales in Volume by Region (2016-2026)
4.1.2 Global Alzheimer’s Pipeline Drugs Revenue by Region (2016-2026)
4.2 North America Alzheimer’s Pipeline Drugs Revenue (2016-2026)
4.3 Europe Alzheimer’s Pipeline Drugs Revenue (2016-2026)
4.4 Asia-Pacific Alzheimer’s Pipeline Drugs Revenue (2016-2026)
4.5 South America Alzheimer’s Pipeline Drugs Revenue (2016-2026)
4.6 Middle East and Africa Alzheimer’s Pipeline Drugs Revenue (2016-2026)
5 Market Segment by Type
5.1 Global Alzheimer’s Pipeline Drugs Sales in Volume by Type (2016-2026)
5.2 Global Alzheimer’s Pipeline Drugs Revenue by Type (2016-2026)
5.3 Global Alzheimer’s Pipeline Drugs Price by Type (2016-2026)
6 Market Segment by Application
6.1 Global Alzheimer’s Pipeline Drugs Sales in Volume by Application (2016-2026)
6.2 Global Alzheimer’s Pipeline Drugs Revenue by Application (2016-2026)
6.3 Global Alzheimer’s Pipeline Drugs Price by Application (2016-2026)
7 North America by Country, by Type, and by Application
7.1 North America Alzheimer’s Pipeline Drugs Sales by Type (2016-2026)
7.2 North America Alzheimer’s Pipeline Drugs Sales by Application (2016-2026)
7.3 North America Alzheimer’s Pipeline Drugs Market Size by Country
7.3.1 North America Alzheimer’s Pipeline Drugs Sales in Volume by Country (2016-2026)
7.3.2 North America Alzheimer’s Pipeline Drugs Revenue by Country (2016-2026)
7.3.3 United States Market Size and Forecast (2016-2026)
7.3.4 Canada Market Size and Forecast (2016-2026)
7.3.5 Mexico Market Size and Forecast (2016-2026)
8 Europe by Country, by Type, and by Application
8.1 Europe Alzheimer’s Pipeline Drugs Sales by Type (2016-2026)
8.2 Europe Alzheimer’s Pipeline Drugs Sales by Application (2016-2026)
8.3 Europe Alzheimer’s Pipeline Drugs Market Size by Country
8.3.1 Europe Alzheimer’s Pipeline Drugs Sales in Volume by Country (2016-2026)
8.3.2 Europe Alzheimer’s Pipeline Drugs Revenue by Country (2016-2026)
8.3.3 Germany Market Size and Forecast (2016-2026)
8.3.4 France Market Size and Forecast (2016-2026)
8.3.5 United Kingdom Market Size and Forecast (2016-2026)
8.3.6 Russia Market Size and Forecast (2016-2026)
8.3.7 Italy Market Size and Forecast (2016-2026)
9 Asia-Pacific by Country, by Type, and by Application
9.1 Asia-Pacific Alzheimer’s Pipeline Drugs Sales by Type (2016-2026)
9.2 Asia-Pacific Alzheimer’s Pipeline Drugs Sales by Application (2016-2026)
9.3 Asia-Pacific Alzheimer’s Pipeline Drugs Market Size by Region
9.3.1 Asia-Pacific Alzheimer’s Pipeline Drugs Sales in Volume by Region (2016-2026)
9.3.2 Asia-Pacific Alzheimer’s Pipeline Drugs Revenue by Region (2016-2026)
9.3.3 China Market Size and Forecast (2016-2026)
9.3.4 Japan Market Size and Forecast (2016-2026)
9.3.5 Korea Market Size and Forecast (2016-2026)
9.3.6 India Market Size and Forecast (2016-2026)
9.3.7 Southeast Asia Market Size and Forecast (2016-2026)
9.3.8 Australia Market Size and Forecast (2016-2026)
10 South America by Country, by Type, and by Application
10.1 South America Alzheimer’s Pipeline Drugs Sales by Type (2016-2026)
10.2 South America Alzheimer’s Pipeline Drugs Sales by Application (2016-2026)
10.3 South America Alzheimer’s Pipeline Drugs Market Size by Country
10.3.1 South America Alzheimer’s Pipeline Drugs Sales in Volume by Country (2016-2026)
10.3.2 South America Alzheimer’s Pipeline Drugs Revenue by Country (2016-2026)
10.3.3 Brazil Market Size and Forecast (2016-2026)
10.3.4 Argentina Market Size and Forecast (2016-2026)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Alzheimer’s Pipeline Drugs Sales by Type (2016-2026)
11.2 Middle East & Africa Alzheimer’s Pipeline Drugs Sales by Application (2016-2026)
11.3 Middle East & Africa Alzheimer’s Pipeline Drugs Market Size by Country
11.3.1 Middle East & Africa Alzheimer’s Pipeline Drugs Sales in Volume by Country (2016-2026)
11.3.2 Middle East & Africa Alzheimer’s Pipeline Drugs Revenue by Country (2016-2026)
11.3.3 Turkey Market Size and Forecast (2016-2026)
11.3.4 Egypt Market Size and Forecast (2016-2026)
11.3.5 Saudi Arabia Market Size and Forecast (2016-2026)
11.3.6 South Africa Market Size and Forecast (2016-2026)
12 Sales Channel, Distributors, Traders and Dealers
12.1 Sales Channel
12.1.1 Direct Marketing
12.1.2 Indirect Marketing
12.2 Alzheimer’s Pipeline Drugs Typical Distributors
12.3 Alzheimer’s Pipeline Drugs Typical Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
Table 1. Global Alzheimer's Pipeline Drugs Revenue by Type, (USD Million), 2021-2026
Table 2. Global Alzheimer's Pipeline Drugs Revenue by Application, (USD Million), 2021-2026
Table 3. Forest Laboratorie Basic Information, Manufacturing Base and Competitors
Table 4. Forest Laboratorie Major Business
Table 5. Forest Laboratorie Alzheimer's Pipeline Drugs Product and Services
Table 6. Forest Laboratorie Alzheimer's Pipeline Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 7. Eisai Basic Information, Manufacturing Base and Competitors
Table 8. Eisai Major Business
Table 9. Eisai Alzheimer's Pipeline Drugs Product and Services
Table 10. Eisai Alzheimer's Pipeline Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 11. H. Lundbeck A/S Basic Information, Manufacturing Base and Competitors
Table 12. H. Lundbeck A/S Major Business
Table 13. H. Lundbeck A/S Alzheimer's Pipeline Drugs Product and Services
Table 14. H. Lundbeck A/S Alzheimer's Pipeline Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 15. Novartis Basic Information, Manufacturing Base and Competitors
Table 16. Novartis Major Business
Table 17. Novartis Alzheimer's Pipeline Drugs Product and Services
Table 18. Novartis Alzheimer's Pipeline Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 19. Merz GmbH & Co. KGaA Basic Information, Manufacturing Base and Competitors
Table 20. Merz GmbH & Co. KGaA Major Business
Table 21. Merz GmbH & Co. KGaA Alzheimer's Pipeline Drugs Product and Services
Table 22. Merz GmbH & Co. KGaA Alzheimer's Pipeline Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 23. Johnson & Johnson Basic Information, Manufacturing Base and Competitors
Table 24. Johnson & Johnson Major Business
Table 25. Johnson & Johnson Alzheimer's Pipeline Drugs Product and Services
Table 26. Johnson & Johnson Alzheimer's Pipeline Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 27. UCB Basic Information, Manufacturing Base and Competitors
Table 28. UCB Major Business
Table 29. UCB Alzheimer's Pipeline Drugs Product and Services
Table 30. UCB Alzheimer's Pipeline Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 31. Global Alzheimer's Pipeline Drugs Sales by Manufacturer (2019-2021e) & (K Units)
Table 32. Global Alzheimer's Pipeline Drugs Revenue by Manufacturer (2019-2021e) & (USD Million)
Table 33. Market Position of Manufacturers in Alzheimer's Pipeline Drugs, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2020
Table 34. Global Alzheimer's Pipeline Drugs Production Capacity by Company, (K Units): 2020 VS 2021
Table 35. Head Office and Alzheimer's Pipeline Drugs Production Site of Key Manufacturer
Table 36. Global Alzheimer's Pipeline Drugs Sales by Region (2016-2021e) & (K Units)
Table 37. Global Alzheimer's Pipeline Drugs Sales by Region (2021-2026) & (K Units)
Table 38. Global Alzheimer's Pipeline Drugs Revenue by Region (2016-2021e) & (USD Million)
Table 39. Global Alzheimer's Pipeline Drugs Revenue by Region (2021-2026) & (USD Million)
Table 40. Global Alzheimer's Pipeline Drugs Sales by Type (2016-2021e) & (K Units)
Table 41. Global Alzheimer's Pipeline Drugs Sales by Type (2021-2026) & (K Units)
Table 42. Global Alzheimer's Pipeline Drugs Revenue by Type (2016-2021e) & (USD Million)
Table 43. Global Alzheimer's Pipeline Drugs Revenue by Type (2021-2026) & (USD Million)
Table 44. Global Alzheimer's Pipeline Drugs Price by Type (2016-2021e) & (USD/Unit)
Table 45. Global Alzheimer's Pipeline Drugs Price by Type (2021-2026) & (USD/Unit)
Table 46. Global Alzheimer's Pipeline Drugs Sales by Application (2016-2021e) & (K Units)
Table 47. Global Alzheimer's Pipeline Drugs Sales by Application (2021-2026) & (K Units)
Table 48. Global Alzheimer's Pipeline Drugs Revenue by Application (2016-2021e) & (USD Million)
Table 49. Global Alzheimer's Pipeline Drugs Revenue by Application (2021-2026) & (USD Million)
Table 50. Global Alzheimer's Pipeline Drugs Price by Application (2016-2021e) & (USD/Unit)
Table 51. Global Alzheimer's Pipeline Drugs Price by Application (2021-2026) & (USD/Unit)
Table 52. North America Alzheimer's Pipeline Drugs Sales by Country (2016-2021e) & (K Units)
Table 53. North America Alzheimer's Pipeline Drugs Sales by Country (2021-2026) & (K Units)
Table 54. North America Alzheimer's Pipeline Drugs Revenue by Country (2016-2021e) & (USD Million)
Table 55. North America Alzheimer's Pipeline Drugs Revenue by Country (2021-2026) & (USD Million)
Table 56. North America Alzheimer's Pipeline Drugs Sales by Type (2016-2021e) & (K Units)
Table 57. North America Alzheimer's Pipeline Drugs Sales by Type (2021-2026) & (K Units)
Table 58. North America Alzheimer's Pipeline Drugs Sales by Application (2016-2021e) & (K Units)
Table 59. North America Alzheimer's Pipeline Drugs Sales by Application (2021-2026) & (K Units)
Table 60. Europe Alzheimer's Pipeline Drugs Sales by Country (2016-2021e) & (K Units)
Table 61. Europe Alzheimer's Pipeline Drugs Sales by Country (2021-2026) & (K Units)
Table 62. Europe Alzheimer's Pipeline Drugs Revenue by Country (2016-2021e) & (USD Million)
Table 63. Europe Alzheimer's Pipeline Drugs Revenue by Country (2021-2026) & (USD Million)
Table 64. Europe Alzheimer's Pipeline Drugs Sales by Type (2016-2021e) & (K Units)
Table 65. Europe Alzheimer's Pipeline Drugs Sales by Type (2021-2026) & (K Units)
Table 66. Europe Alzheimer's Pipeline Drugs Sales by Application (2016-2021e) & (K Units)
Table 67. Europe Alzheimer's Pipeline Drugs Sales by Application (2021-2026) & (K Units)
Table 68. Asia-Pacific Alzheimer's Pipeline Drugs Sales by Region (2016-2021e) & (K Units)
Table 69. Asia-Pacific Alzheimer's Pipeline Drugs Sales by Region (2021-2026) & (K Units)
Table 70. Asia-Pacific Alzheimer's Pipeline Drugs Revenue by Region (2016-2021e) & (USD Million)
Table 71. Asia-Pacific Alzheimer's Pipeline Drugs Revenue by Region (2021-2026) & (USD Million)
Table 72. Asia-Pacific Alzheimer's Pipeline Drugs Sales by Type (2016-2021e) & (K Units)
Table 73. Asia-Pacific Alzheimer's Pipeline Drugs Sales by Type (2021-2026) & (K Units)
Table 74. Asia-Pacific Alzheimer's Pipeline Drugs Sales by Application (2016-2021e) & (K Units)
Table 75. Asia-Pacific Alzheimer's Pipeline Drugs Sales by Application (2021-2026) & (K Units)
Table 76. South America Alzheimer's Pipeline Drugs Sales by Country (2016-2021e) & (K Units)
Table 77. South America Alzheimer's Pipeline Drugs Sales by Country (2021-2026) & (K Units)
Table 78. South America Alzheimer's Pipeline Drugs Revenue by Country (2016-2021e) & (USD Million)
Table 79. South America Alzheimer's Pipeline Drugs Revenue by Country (2021-2026) & (USD Million)
Table 80. South America Alzheimer's Pipeline Drugs Sales by Type (2016-2021e) & (K Units)
Table 81. South America Alzheimer's Pipeline Drugs Sales by Type (2021-2026) & (K Units)
Table 82. South America Alzheimer's Pipeline Drugs Sales by Application (2016-2021e) & (K Units)
Table 83. South America Alzheimer's Pipeline Drugs Sales by Application (2021-2026) & (K Units)
Table 84. Middle East & Africa Alzheimer's Pipeline Drugs Sales by Country (2016-2021e) & (K Units)
Table 85. Middle East & Africa Alzheimer's Pipeline Drugs Sales by Country (2021-2026) & (K Units)
Table 86. Middle East & Africa Alzheimer's Pipeline Drugs Revenue by Country (2016-2021e) & (USD Million)
Table 87. Middle East & Africa Alzheimer's Pipeline Drugs Revenue by Country (2021-2026) & (USD Million)
Table 88. Middle East & Africa Alzheimer's Pipeline Drugs Sales by Type (2016-2021e) & (K Units)
Table 89. Middle East & Africa Alzheimer's Pipeline Drugs Sales by Type (2021-2026) & (K Units)
Table 90. Middle East & Africa Alzheimer's Pipeline Drugs Sales by Application (2016-2021e) & (K Units)
Table 91. Middle East & Africa Alzheimer's Pipeline Drugs Sales by Application (2021-2026) & (K Units)
Table 92. Direct Channel Pros & Cons
Table 93. Indirect Channel Pros & Cons
Table 94. Alzheimer's Pipeline Drugs Typical Distributors
Table 95. Alzheimer's Pipeline Drugs Typical Customers
List of Figures
Figure 1. Alzheimer's Pipeline Drugs Picture
Figure 2. Global Alzheimer's Pipeline Drugs Sales Market Share by Type in 2020
Figure 3. Namenda
Figure 4. Ebixa
Figure 5. Axura
Figure 6. Aricept
Figure 7. Nootropil
Figure 8. Exelon
Figure 9. Memary
Figure 10. Solanezumab
Figure 11. LuAe58054
Figure 12. Global Alzheimer's Pipeline Drugs Sales Market Share by Application in 2020
Figure 13. Hospital
Figure 14. Drug Store
Figure 15. Global Alzheimer's Pipeline Drugs Market Size, (USD Million) & (K Units): 2020 VS 2021 VS 2026
Figure 16. Global Alzheimer's Pipeline Drugs Market Size and Forecast (2016-2026) & (USD Million)
Figure 17. United States Alzheimer's Pipeline Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 18. Canada Alzheimer's Pipeline Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 19. Mexico Alzheimer's Pipeline Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 20. Germany Alzheimer's Pipeline Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 21. France Alzheimer's Pipeline Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 22. United Kingdom Alzheimer's Pipeline Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 23. Russia Alzheimer's Pipeline Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 24. Italy Alzheimer's Pipeline Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 25. China Alzheimer's Pipeline Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 26. Japan Alzheimer's Pipeline Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 27. Korea Alzheimer's Pipeline Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 28. India Alzheimer's Pipeline Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 29. Southeast Asia Alzheimer's Pipeline Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 30. Australia Alzheimer's Pipeline Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 31. Brazil Alzheimer's Pipeline Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 32. Egypt Alzheimer's Pipeline Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 33. Saudi Arabia Alzheimer's Pipeline Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 34. South Africa Alzheimer's Pipeline Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 35. Turkey Alzheimer's Pipeline Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 36. Global Alzheimer's Pipeline Drugs Sales (2016-2026) & (K Units)
Figure 37. Global Alzheimer's Pipeline Drugs Production Capacity (2016-2026) & (K Units)
Figure 38. Global Alzheimer's Pipeline Drugs Production Capacity by Geographic Region: 2020 VS 2021
Figure 39. Alzheimer's Pipeline Drugs Market Drivers
Figure 40. Alzheimer's Pipeline Drugs Market Restraints
Figure 41. Alzheimer's Pipeline Drugs Market Trends
Figure 42. Global Alzheimer's Pipeline Drugs Sales Market Share by Manufacturer in 2020
Figure 43. Global Alzheimer's Pipeline Drugs Revenue Market Share by Manufacturer in 2020
Figure 44. Alzheimer's Pipeline Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 45. Top 3 Alzheimer's Pipeline Drugs Manufacturer (Revenue) Market Share in 2020
Figure 46. Top 6 Alzheimer's Pipeline Drugs Manufacturer (Revenue) Market Share in 2020
Figure 47. Global Alzheimer's Pipeline Drugs Sales Market Share by Region (2016-2026)
Figure 48. Global Alzheimer's Pipeline Drugs Revenue Market Share by Region (2016-2026)
Figure 49. North America Alzheimer's Pipeline Drugs Revenue (2016-2026) & (USD Million)
Figure 50. Europe Alzheimer's Pipeline Drugs Revenue (2016-2026) & (USD Million)
Figure 51. Asia-Pacific Alzheimer's Pipeline Drugs Revenue (2016-2026) & (USD Million)
Figure 52. South America Alzheimer's Pipeline Drugs Revenue (2016-2026) & (USD Million)
Figure 53. Middle East & Africa Alzheimer's Pipeline Drugs Revenue (2016-2026) & (USD Million)
Figure 54. Global Alzheimer's Pipeline Drugs Sales Market Share by Type (2016-2026)
Figure 55. Global Alzheimer's Pipeline Drugs Revenue Market Share by Type (2016-2026)
Figure 56. Global Alzheimer's Pipeline Drugs Price by Type (2016-2026) & (USD/Unit)
Figure 57. Global Alzheimer's Pipeline Drugs Sales Market Share by Application (2016-2026)
Figure 58. Global Alzheimer's Pipeline Drugs Revenue Market Share by Application (2016-2026)
Figure 59. Global Alzheimer's Pipeline Drugs Price by Application (2016-2026) & (USD/Unit)
Figure 60. North America Alzheimer's Pipeline Drugs Sales Market Share by Country (2016-2026)
Figure 61. North America Alzheimer's Pipeline Drugs Revenue Market Share by Country (2016-2026)
Figure 62. North America Alzheimer's Pipeline Drugs Sales Market Share by Type (2016-2026)
Figure 63. North America Alzheimer's Pipeline Drugs Sales Market Share by Application (2016-2026)
Figure 64. Europe Alzheimer's Pipeline Drugs Sales Market Share by Country (2016-2026)
Figure 65. Europe Alzheimer's Pipeline Drugs Revenue Market Share by Country (2016-2026)
Figure 66. Europe Alzheimer's Pipeline Drugs Sales Market Share by Type (2016-2026)
Figure 67. Europe Alzheimer's Pipeline Drugs Sales Market Share by Application (2016-2026)
Figure 68. Asia-Pacific Alzheimer's Pipeline Drugs Sales Market Share by Region (2016-2026)
Figure 69. Asia-Pacific Alzheimer's Pipeline Drugs Revenue Market Share by Region (2016-2026)
Figure 70. Asia-Pacific Alzheimer's Pipeline Drugs Sales Market Share by Region (2016-2026)
Figure 71. Asia-Pacific Alzheimer's Pipeline Drugs Sales Market Share by Application (2016-2026)
Figure 72. South America Alzheimer's Pipeline Drugs Sales Market Share by Country (2016-2026)
Figure 73. South America Alzheimer's Pipeline Drugs Revenue Market Share by Country (2016-2026)
Figure 74. South America Alzheimer's Pipeline Drugs Sales Market Share by Type (2016-2026)
Figure 75. South America Alzheimer's Pipeline Drugs Sales Market Share by Application (2016-2026)
Figure 76. Middle East & Africa Alzheimer's Pipeline Drugs Sales Market Share by Country (2016-2026)
Figure 77. Middle East & Africa Alzheimer's Pipeline Drugs Revenue Market Share by Country (2016-2026)
Figure 78. Middle East & Africa Alzheimer's Pipeline Drugs Sales Market Share by Type (2016-2026)
Figure 79. Middle East & Africa Alzheimer's Pipeline Drugs Sales Market Share by Application (2016-2026)
Figure 80. Sales Channel: Direct Channel vs Indirect Channel
Figure 81. Methodology
Figure 82. Research Process and Data Source
世界のアルツハイマー病治療・診断市場規模・現状・予測（2021年-2027年） Alzheimer’s disease (AD) is the most common reason of progressive dementia in the elderly population. There has been an exponential rise in the number of cases of Alzheimer’s disease worldwide emphasizing the necessity for developing an effective treatment. According to Alzheimer’s Association, in 2…- 世界のアルツハイマー病治療薬市場 2021：企業別、地域別、種類・用途別 The Alzheimer’s Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, …
- 世界のアルツハイマー市場規模・現状・予測（2021年-2027年） Alzheimer’s is a neurodegenerative progressive disease. Alzheimer's disease is a type of dementia whichludes a broad group of brain diseasessuch as problems with memorythinkingand behavior for the long term. It is a type of dementia and near about 60-70% of Alzheimer's disease is the cause of dement…
- 世界のアルツハイマー病治療・診断市場規模・現状・予測（2021年-2027年） Alzheimers is a neurodegenerative disorder that mostly occurs with aging and is a leading cause of dementia. Alzheimers is one of the leading causes of death in the United States, with more than 5 million Americans diagnosed with this dreaded disease, in year 2014. Market Analysis and Insights: Glob…
- 世界のがんワクチン薬剤用パイプライン市場規模・現状・予測（2021年-2027年） Cancer vaccines offer an attractive therapeutic addition, delivering treatment of high specificity, low toxicity and prolonged activity. Germany, the U.S. and Japan represent the largest markets for cancer vaccine manufacturers. Market Analysis and Insights: Global Cancer Vaccines Drug Pipeline Mark…